A three-drug combination, including the novel molecularly targeted agent bortezomib, the first
drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small
cell lung cancer, according to phase I trial results reported recently at the annual meeting of the American
Society of Clinical Oncologists.
The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for
advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology and oncology at
UC Davis Cancer Center and principal investigator of the phase I trial, will also lead the phase II trial.
The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent
an accepted first-line treatment combination for advanced non-small cell lung cancer. Bortezomib is a
proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result
is a buildup of proteins that hastens cell death